top of page

AMR issues from cystitis treatments

Writer's picture: Gabriel KornGabriel Korn

From our Chief Medical Director, Professor Scott Glickman:


With people working on AMR from cystitis treatments, I would be grateful to discuss the following conundrum.


My analysis indicates that the oral/systemic route of administration is critically flawed by rate-limited initial drug filtration and ureteric drip-feed of antibiotic into urinary pools of sufficient volumes to delay it reaching MIC, and with its fluctuant pH likely dynamically altering MIC in-vivo as well, thus potentially providing a window of opportunity for bacteria to react in defence before therapeutic threshold is reached, but haven't determined if it can be tested experimentally, because there are too many uncontrollable variables.


Does anybody have any helpful ideas or is modelling the only option?


You can follow this thread in UroPharma's LinkedIn page https://www.linkedin.com/feed/update/urn:li:activity:7148285732493684736


4 views0 comments

Recent Posts

See All

Aiming at the right urological targets

Last week, Professor of urology, Chris Chapple had a review published in  Continence , titled “The sensory system is a target for...

Anachronistic Bladder Treatments

During much of my medical career, my understanding of the human bladder was that it was a reservoir for the body’s metabolic waste and...

Drugs and dementia

Colleagues While I applaud last week’s publication of the Lancet Commission report on Dementia 2024 that provided updated information on...

Comments


Contact Us

Tel: +44 (0) 1603 626 960

​

Email: info@uropharma.com

©2017-2021 UroPharma, Inc. All Rights Reserved

3.png
2.png

Social Media

  • LinkedIn Social Icon

Linkedin.com/company/uropharma

  • Twitter

Twitter.com/UroPharma

  • Facebook

Facebook.com/bladdercontrol

4_edited_edited.jpg
image.png
bottom of page